Guatemala City, Guatemala

Guillermo E Sanchez

This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Other. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guillermo E Sanchez. Retrieved from https://idiyas.com/inventor/guillermo-e-sanchez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:

goldMedal2 out of 834,659 
Other
 patents

Years Active: 2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Guillermo E Sanchez Revolutionizes Nutrition with Patented Nutraceutical Formulations

Introduction:

In the realm of innovations and patents, Guillermo E Sanchez is a pioneering force to be reckoned with. Hailing from Guatemala, GT, Sanchez has made remarkable contributions to the field of nutrition by developing nutraceutical formulations that bring about positive health outcomes. With two patents under his belt, Sanchez's groundbreaking work focuses on mitigating chronic infant malnutrition and managing conditions related to type 2 diabetes. Let's dive into the details of his innovative patents and collaborative work with co-inventor Glenn H Sullivan.

Mitigation of Chronic Infant Malnutrition:

One of Guillermo E Sanchez's key patents revolves around the mitigation of chronic infant malnutrition. The patented nutraceutical formulations provide essential nutrients and supplements to breastfeeding infants. By developing a prescribed regimen that incorporates these nutraceuticals, infants can benefit from the improved nutritional intake resulting from lactating mothers ingesting the formulations. This innovative approach has the potential to positively impact the health and development of infants, addressing a critical issue that affects many communities worldwide.

Nutraceuticals for the Management of Conditions Related to Type 2 Diabetes:

Sanchez's second patented innovation marks a significant advancement in the management and remediation of conditions related to type 2 diabetes. His nutraceutical formulations are specifically designed to leverage the hydrophilic and lipophilic fractions of stabilized rice bran. These nutraceuticals not only aim to decrease HbAc and fasting glucose blood concentrations but also seek to increase serum fasting insulin levels. By providing a natural and proactive approach to managing type 2 diabetes, Sanchez's invention has the potential to improve the quality of life for individuals living with this condition.

Collaboration with Glenn H Sullivan:

Glenn H Sullivan, a co-inventor and collaborator of Guillermo E Sanchez, has played an integral role in the development of these patented nutraceutical formulations. As a team, both innovators have combined their knowledge and expertise to create groundbreaking solutions. The collaboration allows for a more comprehensive approach, ensuring that their inventions are well-rounded and effective in addressing the targeted health concerns.

Conclusion:

Guillermo E Sanchez's contribution to the field of nutrition, specifically in the areas of infant malnutrition and type 2 diabetes management, cannot be overstated. Through his patented nutraceutical formulations, Sanchez has demonstrated his commitment to improving lives through innovative solutions. With a focus on both preventive and remedial measures, his work presents promising avenues for better health outcomes. We eagerly anticipate further breakthroughs from Sanchez and his collaboration with Glenn H Sullivan, as they continue to pave the way for transformative innovations in the field of nutrition. For more information on their inventions and patents, visit idiyas.com.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…